secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2024-10-24T23:59:59+00:00
Accession:  0000950170-24-116864
Event type: regulatory
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences reports ~$121M cash, gets first CTA approval for PBGENE-HBV in Moldova
--------------------------------------------------------------------------------

- Expected cash, cash equivalents, and restricted cash of ~$121M as of Sept 30, 2024 (preliminary, unaudited).
- Received CTA approval in Moldova for PBGENE-HBV, a first-in-human in vivo gene editing study for chronic hepatitis B.
- PBGENE-HBV targets and eliminates cccDNA and inactivates integrated HBV DNA, aiming for functional cure.
- Company to host investor event on Nov 15, 2024 prior to AASLD meeting to share preclinical safety package and Phase 1 trial details.
- Additional global CTA and IND submissions underway to accelerate patient enrollment across multiple sites.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000095017024116864/0000950170-24-116864-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000095017024116864/dtil-20241024.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-116864

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer